Anti-Rheumatic Drugs - Botswana | Statista Market Forecast

The market for Anti-Rheumatic Drugs market in Botswana is anticipated to witness a significant increase in revenue, with projections indicating that it will reach US$2.48m in 2024.
Moreover, there is an expected annual growth rate (CAGR 2024-2029) of 1.18%, which will contribute to a market volume of US$2.63m by 2029.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue, amounting to US$34.70bn in 2024.
Botswana's demand for anti-rheumatic drugs is rising steadily due to the increasing prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Botswana has been experiencing steady growth in recent years.

Customer preferences: Patients in Botswana suffering from rheumatoid arthritis and other autoimmune diseases have been increasingly seeking effective treatments to manage their conditions. As a result, there has been a growing demand for Anti-Rheumatic Drugs in the country. Patients are also becoming more aware of the importance of early diagnosis and treatment, leading to an increase in the number of people seeking medical attention for their symptoms.

Trends in the market: The Anti-Rheumatic Drugs market in Botswana has been expanding due to the rising prevalence of rheumatoid arthritis and other autoimmune diseases in the country. The market is expected to continue growing as the population ages and the incidence of these conditions increases. Additionally, there has been a shift towards the use of biologic agents, which are more effective in managing symptoms and have fewer side effects than traditional disease-modifying anti-rheumatic drugs (DMARDs).

Local special circumstances: Botswana faces unique challenges when it comes to healthcare, including a shortage of healthcare professionals and limited resources. This has led to a lack of access to specialized care and treatments for patients with rheumatoid arthritis and other autoimmune diseases. The government has been working to address these issues by investing in healthcare infrastructure and training more healthcare professionals to meet the growing demand for specialized care.

Underlying macroeconomic factors: Botswana has a growing economy and a relatively stable political environment, which has helped to support the growth of the Anti-Rheumatic Drugs market. Additionally, the government has been investing in healthcare infrastructure, which has improved access to healthcare services across the country. However, the country still faces challenges related to poverty and inequality, which can impact access to healthcare for some segments of the population.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.